1. Home
  2. CBL vs VRDN Comparison

CBL vs VRDN Comparison

Compare CBL & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CBL & Associates Properties Inc.

CBL

CBL & Associates Properties Inc.

HOLD

Current Price

$48.00

Market Cap

1.4B

Sector

Real Estate

ML Signal

HOLD

Logo Viridian Therapeutics Inc.

VRDN

Viridian Therapeutics Inc.

HOLD

Current Price

$17.50

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CBL
VRDN
Founded
1978
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Medical Specialities
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.4B
IPO Year
1995
2014

Fundamental Metrics

Financial Performance
Metric
CBL
VRDN
Price
$48.00
$17.50
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
14
Target Price
$45.00
$35.46
AVG Volume (30 Days)
213.3K
3.1M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
4.00%
N/A
EPS Growth
132.09
N/A
EPS
1.48
N/A
Revenue
$578,373,000.00
$5,706,000.00
Revenue This Year
N/A
$13.73
Revenue Next Year
N/A
$279.00
P/E Ratio
$32.71
N/A
Revenue Growth
12.18
N/A
52 Week Low
$24.33
$13.18
52 Week High
$49.18
$34.29

Technical Indicators

Market Signals
Indicator
CBL
VRDN
Relative Strength Index (RSI) 65.24 53.55
Support Level $36.41 $15.65
Resistance Level $48.64 $17.90
Average True Range (ATR) 1.45 0.82
MACD 0.00 0.24
Stochastic Oscillator 71.58 72.35

Price Performance

Historical Comparison
CBL
VRDN

About CBL CBL & Associates Properties Inc.

CBL & Associates Properties Inc is a real estate investment trust. The company engages in the ownership, development, acquisition, leasing, management and operation of regional shopping malls, outlet centers, lifestyle centers, open-air centers and other properties. CBL's sales predominantly derive from leasing arrangements with retail tenants. The company also generates revenue from management and development fees, as well as sales of its real estate assets. CBL expands its portfolio of assets through activities such as redevelopment, renovation, and expansion.

About VRDN Viridian Therapeutics Inc.

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.

Share on Social Networks: